AP NEWS

Global Autoimmune Drugs Market Forecast to 2022; Led by AbbVie, Amgen, Johnson & Johnson, Novartis, Pfizer and UCB - ResearchAndMarkets.com

January 7, 2019

DUBLIN--(BUSINESS WIRE)--Jan 7, 2019--The “Global Autoimmune Drugs Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The autoimmune drugs market will register a CAGR of more than 8% by 2022.

High cost of autoimmune drugs to drive market growth

Governments and regulatory bodies have undertaken several initiatives to reduce the costs of therapies for autoimmune disorders mainly rheumatoid arthritis. Despite these efforts, autoimmune drugs continue to remain expensive. Biologics and biosimilars are expensive when compared with conventional therapies such as NSAIDs.

Targeted therapeutic mechanism of biologics

By providing a targeted action, biologics tend to be more effective and have lesser side effects compared with small molecule agents. Hence, the introduction of biologic therapy to manage autoimmune disorders is driving the market at a very rapid pace.

Reimbursement challenges of autoimmune drugs

The insurers are reluctant to provide reimbursement for the drugs for treatment of autoimmune diseases due to the lack of knowledge; therefore, they generally do not provide any provisions for the reimbursement of drugs for rheumatoid arthritis and other autoimmune diseases.

Key Players

AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

Market ecosystem Market characteristics Market segmentation analysis

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

Market definition Market sizing 2017 Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY THERAPY AREA

Segmentation by therapy area Comparison by therapy area Rheumatoid arthritis - Market size and forecast 2017-2022 Multiple sclerosis - Market size and forecast 2017-2022 Psoriasis - Market size and forecast 2017-2022 Inflammatory bowel disease - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by therapy area

PART 09: MARKET SEGMENTATION BY TYPE OF MOLECULE

Segmentation by type of molecule Biologics Small molecules

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

Geographical segmentation Regional comparison Americas - Market size and forecast 2017-2022 EMEA - Market size and forecast 2017-2022 APAC - Market size and forecast 2017-2022 Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

Overview Landscape disruption

PART 16: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Novartis Pfizer UCB

For more information about this report visit https://www.researchandmarkets.com/research/5j7gz5/global_autoimmune?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190107005509/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/07/2019 06:00 AM/DISC: 01/07/2019 06:01 AM

http://www.businesswire.com/news/home/20190107005509/en

AP RADIO
Update hourly